Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Taysha Gene Therapies Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TSHA
Nasdaq
8731
https://tayshagtx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Taysha Gene Therapies Inc
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- May 3rd, 2024 8:05 pm
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
- May 2nd, 2024 2:01 pm
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
- May 2nd, 2024 12:00 pm
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
- Apr 29th, 2024 5:37 pm
Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher
- Apr 20th, 2024 1:58 pm
Certain Biotech Investors Get an Early Look at Results. Is That Fair?
- Apr 15th, 2024 9:30 am
News Flash: Analysts Just Made A Notable Upgrade To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Forecasts
- Mar 24th, 2024 12:17 pm
Taysha Gene Therapies Full Year 2023 Earnings: Beats Expectations
- Mar 21st, 2024 10:34 am
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript
- Mar 20th, 2024 3:19 pm
Q4 2023 Taysha Gene Therapies Inc Earnings Call
- Mar 20th, 2024 12:01 pm
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
- Mar 19th, 2024 8:01 pm
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
- Mar 14th, 2024 8:26 pm
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
- Feb 29th, 2024 1:00 pm
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
- Feb 15th, 2024 9:01 pm
Owning 39% shares,institutional owners seem interested in Taysha Gene Therapies, Inc. (NASDAQ:TSHA),
- Feb 13th, 2024 10:54 am
7 Micro-Cap Stocks That Could Majorly Surprise Investors
- Jan 31st, 2024 7:23 pm
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
- Jan 22nd, 2024 1:00 pm
3 Growth Stocks That Could Go Parabolic in 2024
- Jan 15th, 2024 2:30 pm
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
- Jan 10th, 2024 1:00 pm
Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies
- Dec 19th, 2023 12:30 pm
Scroll